- Home
- PAM vs KRYS Comparison
PAM vs KRYS Comparison
Compare PAM & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAM
- KRYS
- Stock Information
- Founded
- PAM 1945
- KRYS 2015
- Country
- PAM Argentina
- KRYS United States
- Employees
- PAM N/A
- KRYS N/A
- Industry
- PAM Electric Utilities: Central
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAM Utilities
- KRYS Health Care
- Exchange
- PAM Nasdaq
- KRYS Nasdaq
- Market Cap
- PAM 3.9B
- KRYS 3.6B
- IPO Year
- PAM N/A
- KRYS 2017
- Fundamental
- Price
- PAM $76.63
- KRYS $125.96
- Analyst Decision
- PAM Buy
- KRYS Strong Buy
- Analyst Count
- PAM 4
- KRYS 8
- Target Price
- PAM $75.88
- KRYS $211.13
- AVG Volume (30 Days)
- PAM 200.7K
- KRYS 436.2K
- Earning Date
- PAM 05-12-2025
- KRYS 05-06-2025
- Dividend Yield
- PAM N/A
- KRYS N/A
- EPS Growth
- PAM 32.60
- KRYS 109.01
- EPS
- PAM 0.41
- KRYS 4.16
- Revenue
- PAM $1,970,436,590.00
- KRYS $333,448,000.00
- Revenue This Year
- PAM $127,194.51
- KRYS $48.66
- Revenue Next Year
- PAM $22.99
- KRYS $49.81
- P/E Ratio
- PAM $7.46
- KRYS $30.31
- Revenue Growth
- PAM 21.62
- KRYS 247.53
- 52 Week Low
- PAM $38.58
- KRYS $122.80
- 52 Week High
- PAM $97.55
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- PAM 45.40
- KRYS 31.65
- Support Level
- PAM $78.75
- KRYS $123.03
- Resistance Level
- PAM $82.78
- KRYS $127.59
- Average True Range (ATR)
- PAM 3.74
- KRYS 4.59
- MACD
- PAM -0.48
- KRYS 0.39
- Stochastic Oscillator
- PAM 7.72
- KRYS 18.15
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business. The operating business segments of the firm are Electricity generation, Electricity distribution, Oil and Gas, Petrochemicals, and Holding and other business. The company derives the maximum revenue from the Distribution of energy.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.